208 related articles for article (PubMed ID: 15468186)
1. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.
Smith MR; Manola J; Kaufman DS; George D; Oh WK; Mueller E; Slovin S; Spiegelman B; Small E; Kantoff PW
Cancer; 2004 Oct; 101(7):1569-74. PubMed ID: 15468186
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.
Smith MR; Manola J; Kaufman DS; Oh WK; Bubley GJ; Kantoff PW
J Clin Oncol; 2006 Jun; 24(18):2723-8. PubMed ID: 16782912
[TBL] [Abstract][Full Text] [Related]
4. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM;
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837
[TBL] [Abstract][Full Text] [Related]
5. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma.
Beer TM; Lemmon D; Lowe BA; Henner WD
Cancer; 2003 Mar; 97(5):1217-24. PubMed ID: 12599228
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
[TBL] [Abstract][Full Text] [Related]
7. Radical prostatectomy for clinical stage T3a disease.
Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
[TBL] [Abstract][Full Text] [Related]
8. Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era.
Lin DD; Schultz D; Renshaw AA; Rubin MA; Richie JP; D'Amico AV
Urology; 2005 Mar; 65(3):528-32. PubMed ID: 15780370
[TBL] [Abstract][Full Text] [Related]
9. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
10. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy.
Goluboff ET; Prager D; Rukstalis D; Giantonio B; Madorsky M; Barken I; Weinstein IB; Partin AW; Olsson CA;
J Urol; 2001 Sep; 166(3):882-6. PubMed ID: 11490238
[TBL] [Abstract][Full Text] [Related]
12. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy.
Shimizu F; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M
Urol Int; 2007; 79(4):356-60. PubMed ID: 18025856
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer.
Siemens DR; Heaton JP; Adams MA; Kawakami J; Graham CH
Urology; 2009 Oct; 74(4):878-83. PubMed ID: 19476985
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.
Schröder FH; Roobol MJ; Boevé ER; de Mutsert R; Zuijdgeest-van Leeuwen SD; Kersten I; Wildhagen MF; van Helvoort A
Eur Urol; 2005 Dec; 48(6):922-30; discussion 930-1. PubMed ID: 16263208
[TBL] [Abstract][Full Text] [Related]
16. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
Khatami A; Hugosson J; Wang W; Damber JE
Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
[TBL] [Abstract][Full Text] [Related]
17. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer.
Pantuck AJ; Leppert JT; Zomorodian N; Aronson W; Hong J; Barnard RJ; Seeram N; Liker H; Wang H; Elashoff R; Heber D; Aviram M; Ignarro L; Belldegrun A
Clin Cancer Res; 2006 Jul; 12(13):4018-26. PubMed ID: 16818701
[TBL] [Abstract][Full Text] [Related]
19. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
20. Predictor of response to salvage radiotherapy in patients with PSA recurrence after radical prostatectomy: the usefulness of PSA doubling time.
Numata K; Azuma K; Hashine K; Sumiyoshi Y
Jpn J Clin Oncol; 2005 May; 35(5):256-9. PubMed ID: 15886268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
